| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Obexelimab Systemic Lupus Erythematosus (SLE) | Phase 2 | — | Biologics | Immunology | ||
Top-line Data example | Obexelimab Systemic Lupus Erythematosus (SLE) | Phase 2 | — | Biologics | Immunology | ||
Top-line Data example | Obexelimab Systemic Lupus Erythematosus (SLE) | Phase 2 | — | Biologics | Immunology |
Recent Updates
Recently added Catalysts
Zenas BioPharma, Inc.$20.21
-0.6 (-2.86%)
B 62Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.20 B
EPS
-9.10
P/E Ratio
-
Value Trade
7.25 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
60.44 M
Operating CF
-75.20 M
Total Assets
747.68 M
Total Liabilities
411.85 M
Equity
335.83 M
D/E Ratio
12,345
2.82 %
Week
-8.22 %
1 Month
-28.9 %
3 Month
-45.55 %
6 Month
3.38 %
5 Year
3.38 %
All Time
Cash Data
Cash Position
717.20 M
Monthly Burn
25.07 M
Runway
27.4 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
513.38 K
52 Week Range
8.91 - 44.60
% held by Insiders
45.07 %
% held by Institutions
63.57 %
Enterprise Value
832.16 M
Total Shares
57.34 M
Short %
48.03 %
Float Shares
22.65 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B62
Pipeline Score $2.2B
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.9x
rNPV / MCap Top 90%
Micro Cap (rank 91 of 905)
Percentile RankZenas BioPharma, Inc. holds a solid B-grade pipeline (62/100), with $5.5B risk-adjusted pipeline value, led by Orelabrutinib in Secondary Progressive Multiple Sclerosis (Phase 3), across $70B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orelabrutinib Small molecule | Multiple Sclerosis (MS) Primary Progressive | Phase 3 | NCT07067463 | 58% | $4.2B | RECRUITING | 705 | VERY_FAST | B (62) | Jul 1, 2030 | LOW_RISK | LOW Jun 23, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
obexelimab | IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus | Phase 3 | 2025-09-03 | |||
obexelimab | IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus | Phase 3 | 2025-09-03 | |||
obexelimab | IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus | Phase 3 | 2025-09-03 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZBIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZBIO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ZBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZBIOZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →ZBIOZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The presentation will be available on-demand starting June 15, 2026. Zenas focuses on developing therapies for autoimmune diseases, with two late-stage candidates, obexelimab and orelabrutinib, showing promise in addressing chronic conditions.
Read more →ZBIOZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD). The trial met its primary and secondary endpoints, demonstrating significant reductions in disease activity and glucocorticoid use. A Biologics License Application for obexelimab was submitted to the FDA in May 2026, marking a potential breakthrough in treatment options for this condition.
Read more →ZBIOZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
Zenas BioPharma has submitted a Biologics License Application (BLA) to the FDA for obexelimab, aimed at treating Immunoglobulin G4-Related Disease (IgG4-RD). This submission is supported by positive results from the Phase 3 INDIGO trial, which showed a significant reduction in flare risk. The company believes obexelimab could play a crucial role in managing this chronic condition.
Read more →ZBIOZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
Zenas BioPharma announced that results from the Phase 3 INDIGO trial of obexelimab for IgG4-RD will be presented at the EULAR 2026 Congress. The trial showed a significant reduction in flare risk and met all key endpoints. Obexelimab was well tolerated, with no new safety concerns reported. This presentation marks a critical step in the drug's development.
Read more →ZBIOZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Zenas BioPharma has announced the dosing of the first subject in its Phase 1 clinical trial for ZB021, an oral IL-17AA/AF inhibitor. The trial aims to assess the safety, tolerability, and pharmacokinetics of ZB021 in healthy volunteers, with proof-of-concept data expected in psoriasis patients by 2027. The company anticipates initial clinical data by the end of 2026.
Read more →ZBIOZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported its Q1 2026 financial results, highlighting significant progress in its clinical trials, particularly for obexelimab in treating IgG4-RD. The company is on track to submit marketing applications to the FDA and EMA, with positive results from the Phase 3 INDIGO trial. Additionally, Zenas completed enrollment in the Phase 2 SunStone trial and initiated a Phase 1 trial for ZB021, an oral IL-17AA/AF inhibitor.
Read more →ZBIOZenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Zenas BioPharma has announced concurrent public offerings of convertible senior notes due 2032 and common stock to support its development pipeline and the planned launch of obexelimab. The offerings are not contingent on each other, and there is a risk of lower net proceeds. The company aims to use the funds for clinical trials and general corporate purposes.
Read more →ZBIOZenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Zenas BioPharma has announced the pricing of its public offerings, which include $200 million in convertible senior notes due 2032 and 5 million shares of common stock priced at $20 each. The total expected net proceeds from these offerings are approximately $287.5 million. The funds will primarily support the commercial launch of obexelimab and advance ongoing clinical trials. The offerings are set to close on March 31, 2026, subject to customary conditions.
Read more →ZBIOZenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Obexelimab marketing applications for the treatment of IgG4 RD expected to be submitted to the FDA in Q2 2026 an
Zenas BioPharma has reported its financial results for Q4 and the full year 2025, alongside a corporate update. The company anticipates submitting marketing applications for obexelimab targeting IgG4-RD to the FDA and EMA in the next year. Positive results from the Phase 3 INDIGO trial were noted, with a focus on advancing multiple pipeline programs. Furthermore, Zenas has announced a non-dilutive financing deal to bolster its financial position for upcoming projects.
Read more →ZBIOZenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Zenas BioPharma announced positive results from the Phase 2 MoonStone trial of obexelimab for Relapsing Multiple Sclerosis, showing a 95% reduction in new gadolinium-enhancing lesions compared to placebo. The drug demonstrated sustained efficacy over 24 weeks and was well tolerated. The findings were presented at the ACTRIMS Forum 2026, highlighting obexelimab's potential in autoimmune disease treatment.
Read more →ZBIOZenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Zenas BioPharma announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 11, 2026. The company aims to lead in developing therapies for autoimmune diseases, showcasing its late-stage candidates, obexelimab and orelabrutinib. The presentation will be accessible via a live webcast and archived replay.
Read more →ZBIOZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Zenas BioPharma announced an Inducement Grant on January 15, 2026, providing stock options to a new employee as part of their hiring process. The grant includes 100,000 shares at an exercise price of $19.93, vesting over four years. This move reflects Zenas' commitment to growth and compliance with Nasdaq Listing Rule 5635(c)(4).
Read more →ZBIOZenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab for treating Immunoglobulin G4-Related Disease (IgG4-RD). The trial showed a significant 56% reduction in flare risk and met all key secondary efficacy endpoints. Zenas plans to submit a Biologics License Application to the FDA in Q2 2026 and a Marketing Authorization Application to the EMA later in 2026.
Read more →ZBIOZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025
Zenas BioPharma announced the grant of non-qualified stock options to two new employees as an inducement for their employment. The stock options, totaling 300,000 shares, have a ten-year term with an exercise price set at $32.59. These options will vest over four years, contingent on the employees' continued service. Zenas continues to focus on developing therapies for autoimmune diseases.
Read more →ZBIOZenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
Read more →ZBIOZenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
Zenas BioPharma reported its financial results for Q3 2025, highlighting a successful Phase 2 trial of obexelimab in relapsing multiple sclerosis with highly positive outcomes. The company also secured a significant funding agreement with Royalty Pharma to support the development of its therapies, including three new autoimmune product candidates. Zenas anticipates releasing topline results for its Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease by the end of 2025. These developments indicate a robust position in the competitive biopharmaceutical landscape targeting autoimmune diseases.
Read more →ZBIOZenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Read more →ZBIOZenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 le
Zenas BioPharma announced that its Phase 2 MoonStone trial for obexelimab in relapsing multiple sclerosis has met its primary endpoint, achieving a 95% reduction in gadolinium-enhancing lesions. The trial data demonstrated significant suppression of inflammation markers and a favorable safety profile consistent with previous studies. Zenas plans to further explore obexelimab's benefits in additional autoimmune diseases through ongoing and upcoming trials.
Read more →ZBIOZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - Orela
Zenas BioPharma has announced a transformational licensing agreement with InnoCare Pharma, granting it global rights to develop and commercialize three autoimmune product candidates, including the promising BTK inhibitor, orelabrutinib, currently in Phase 3 development for progressive forms of Multiple Sclerosis. The partnership supports Zenas in executing its vision to become a fully integrated biopharmaceutical company focused on autoimmune disorders. Additionally, Zenas is poised to potentially secure up to $120 million in private placement financing, further solidifying its financial standing. The agreement marks a significant milestone in both companies' efforts to advance innovative therapies and address unmet medical needs.
Read more →ZBIOZenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease
Zenas BioPharma has entered a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease. The initial payment of $75 million will facilitate this launch, while an additional $150 million is contingent upon positive Phase 3 trial results and FDA approval. The innovative bifunctional monoclonal antibody is in late-stage development and aims to address significant unmet needs in autoimmune diseases. The collaboration signifies financial flexibility for Zenas as it accelerates its clinical programs.
Read more →ZBIOZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Comp
Zenas BioPharma reported its second quarter 2025 financial results and corporate updates, highlighting rapid progress in its obexelimab development program. The company completed enrollment for the Phase 2 MoonStone trial in Relapsing Multiple Sclerosis and anticipates topline data from the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease around the end of 2025. Zenas has a cash reserve of $274.9 million, expected to sustain operations into late 2026 as it pursues multiple Phase 2 and Phase 3 trials for its product candidate.
Read more →ZBIOZenas BioPharma Corporate Presentation June 2025 Enabling patients with autoimmune diseases to reimagine life 2 Disclaimer FORWARD - LOOKING STATEMENTS: This presentation contains "forward - looking statements" which inv
Zenas BioPharma presented its corporate strategy focusing on obexelimab, a bifunctional antibody targeting autoimmune diseases, with multiple ongoing clinical trials. The company aims for significant milestones with this candidate, which may create a multi-billion-dollar commercial opportunity. However, it faces inherent risks associated with clinical development, including potential delays and the need for substantial financing. The presentation highlighted their funding status and upcoming trial timelines but acknowledged the uncertainties of regulatory approvals and competition in the market.
Read more →ZBIOZenas BioPharma to Present at the Jefferies Global Healthcare Conference
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
Read more →ZBIOZenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase
Zenas BioPharma reported its financial results for Q1 2025 and provided updates on several pivotal clinical trials. The company anticipates topline results from the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease by year-end 2025, along with results from the Phase 2 MoonStone and SunStone trials in the coming years. Zenas also highlighted the strengthening of its leadership team and emphasized the significant cash reserves, expected to support operations through late 2026.
Read more →ZBIOZenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Read more →ZBIOZenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases - Advancing Phase 2 and Phase 3 trials of obexe
Zenas BioPharma has announced its accomplishments for 2024 and outlined its objectives for 2025, focusing on the global development of therapies for autoimmune diseases, particularly obexelimab. The company expects to advance Phase 2 and Phase 3 clinical trials for obexelimab, targeting multiple sclerosis and immunoglobulin G4-related disease, with significant results anticipated in the upcoming years. Zenas enters 2025 well-funded with a cash reserve that is projected to cover operational expenses substantially. Its innovative approach in targeting B cells demonstrates promise in addressing unmet medical needs in autoimmune diseases.
Read more →ZBIOZenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
Read more →ZBIOZenas BioPharma Corporate Presentation December 2024 Enabling patients with autoimmune diseases to reimagine life 2 Disclaimer FORWARD - LOOKING STATEMENTS This presentation contains "forward - looking statements" which
Zenas BioPharma has presented its corporate strategy and development plans, focusing on creating innovative therapies for autoimmune diseases. Their lead candidate, Obexelimab, targets conditions such as IgG4-RD, RMS, and SLE, representing a substantial commercial opportunity. The company emphasizes its strong operational team and funding status to support ongoing and future clinical trials. However, Zenas also faces notable uncertainties, including the need for additional financing and inherent risks linked to clinical development.
Read more →ZBIOZenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead
Zenas BioPharma reported its third-quarter financial results for 2024, highlighting the successful completion of its initial public offering that raised $258.7 million to fund the clinical development of its lead candidate, obexelimab. The company announced the successful enrollment of the INDIGO Phase 3 trial, which is the largest ever for Immunoglobulin G4-Related Disease. Topline results from this trial are anticipated by the end of 2025. However, the company continues to face financial losses and uncertainties associated with ongoing clinical developments.
Read more →ZBIOZenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Read more →ZBIOZenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Read more →ZBIOZenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
Read more →ZBIOZenas BioPharma Announces Pricing of Upsized Initial Public Offering
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
Read more →ZBIOZenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
Read more →ZBIOZenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
Read more →ZBIOZenas BioPharma Appoints Patricia Allen to its Board of Directors
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Read more →ZBIOZenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph.D., as Head of R&D
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph.D., as Head of R&D
Read more →ZBIOZenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
Read more →ZBIOZenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Read more →ZBIOZenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Read more →ZBIOZenas BioPharma Secures $118 Million to Advance its Broad Pipeline of Autoimmune Disease Therapeutics
Zenas BioPharma Secures $118 Million to Advance its Broad Pipeline of Autoimmune Disease Therapeutics
Read more →ZBIOZenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
Read more →ZBIOZenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
Read more →ZBIOZenas BioPharma Appoints Dr. John Orloff to Board of Directors
Zenas BioPharma Appoints Dr. John Orloff to Board of Directors
Read more →ZBIOZenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Read more →ZBIOZenas BioPharma Announces New Executive Leadership Appointments
Zenas BioPharma Announces New Executive Leadership Appointments
Read more →ZBIOZenas BioPharma Launches
Zenas BioPharma Launches
Read more →Competitive Position
How ZBIO ranks across every disease it competes inCompetitive Position is a premium feature
See how ZBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial